PRODUCT INFORMATION



Eledoisin-related Peptide

Item No. 33115

CAS Registry No.:			
Formal Name:	L-lysyl-L-phenylalanyl-L-isoleucylglycyl-		,
	L-leucyl-L-methioninamide		s
Synonyms:	Eledoisin Hexapeptide,		
	Eledoisin RP, KFIGLM-NH ₂ ,		
	Lys-Phe-Ile-Gly-Leu-Met-NH ₂		
MF:	C ₃₄ H ₅₈ N ₈ O ₆ S	H ₂ N N N N	N NI2
FW:	706.9	NH ₂ H Ö L H Ö L	ΗÖ
Purity:	≥95%		
Supplied as:	A solid		
Storage:	-20°C		
Stability:	≥4 years		
Information represents the product specifications. Batch specific analytical results are provided on each sortificate of analysis			

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Eledoisin-related peptide is supplied as a solid. A stock solution may be made by dissolving the eledoisinrelated peptide in water. We do not recommend storing the aqueous solution for more than one day.

Description

Eledoisin-related peptide is a hexapeptide fragment of eledoisin (Item No. 28810), an undecapeptide tachykinin neuropeptide and neurokinin (NK) receptor agonist.¹⁻³ It induces contractions in isolated guinea pig ileum, as well as α -amylase release from rat parotid gland slices, in a concentration-dependent manner.⁴ Intrathecal administration of eledoisin-related peptide (1.25-10 µg/animal) reduces tail flick latency in the hot plate test.⁵

References

- 1. Evered, M.D., Fitzsimons, J.T., and De Caro, G. Drinking behaviour induced by intracranial injections of eledoisin and substance P in the pigeon. Nature 268(5618), 332-333 (1977).
- 2. Severini, C., Improta, G., Falconieri-Erspamer, G., et al. The tachykinin peptide family. Pharmacol. Rev. 54(2), 285-322 (2002).
- 3. Erspamer, V. and Anastasi, A. Structure and pharmacological actions of eledoisin, the active endecapeptide of the posterior salivary glands of Eledone. Experientia 18(2), 58-59 (1962).
- 4. Gater, P.R., Jordan, C.C., and Owen, D.G. Relative activities of substance P-related peptides in the guineapig ileum and rat parotid gland, in vitro. Br. J. Pharmacol. 75(2), 341-351 (1982).
- Yasphal, K., Wright, D.M., and Henry, J.L. Substance P reduces tail-flick latency: Implications for chronic 5. pain syndromes. Pain 14(2), 155-167 (1982).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/14/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM